FDA expands use of Allergan's Botox to include overactive bladder

01/20/2013 | Reuters · MedPage Today (free registration)

Allergan's Botox, or onabotulinumtoxin A, has been approved by the FDA for use in patients with overactive bladder who can't take or don't improve with anticholinergics. The approval was based on results of two clinical studies showing that Botox reduced the frequency of incontinence and urination compared with placebo.

View Full Article in:

Reuters · MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT